UA5560A1 - СПОСІБ РОЗДІЛЕННЯ СУМІШИ d-І l-ЕНАНТІОМЕРІВ 4-[1- - Google Patents

СПОСІБ РОЗДІЛЕННЯ СУМІШИ d-І l-ЕНАНТІОМЕРІВ 4-[1-

Info

Publication number
UA5560A1
UA5560A1 UA4356076A UA4356076A UA5560A1 UA 5560 A1 UA5560 A1 UA 5560A1 UA 4356076 A UA4356076 A UA 4356076A UA 4356076 A UA4356076 A UA 4356076A UA 5560 A1 UA5560 A1 UA 5560A1
Authority
UA
Ukraine
Prior art keywords
separation
mixture
enanthiomers
dimethylphenyl
imidazole
Prior art date
Application number
UA4356076A
Other languages
English (en)
Russian (ru)
Inventor
Йоханнес Карьялайнен Арто
Ейнарі Віртанен Раімо
Юхані Саволайнен Ейно
Original Assignee
Оріон Іхтюмя Ой
Орион Ихтюмя Ой
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10620775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA5560(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Оріон Іхтюмя Ой, Орион Ихтюмя Ой filed Critical Оріон Іхтюмя Ой
Publication of UA5560A1 publication Critical patent/UA5560A1/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Заявлено спосіб розділення суміші D- і L-енантіомерів 4-[1-(2,3-диметилфеніл)етил]-1Н-імідазолу. Відповідно до способу рацемічний 4-[1-(2,3-диметилфеніл)-1-етил]імідазол обробляють оптично активною кислотою з подальшим розділенням суміші діастереоізомерних солей шляхом фракційної кристалізації.
UA4356076A 1987-07-16 1988-06-28 СПОСІБ РОЗДІЛЕННЯ СУМІШИ d-І l-ЕНАНТІОМЕРІВ 4-[1- UA5560A1 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8716803A GB2206880B (en) 1987-07-16 1987-07-16 Optical isomers of an imidazole derivative

Publications (1)

Publication Number Publication Date
UA5560A1 true UA5560A1 (uk) 1994-12-28

Family

ID=10620775

Family Applications (1)

Application Number Title Priority Date Filing Date
UA4356076A UA5560A1 (uk) 1987-07-16 1988-06-28 СПОСІБ РОЗДІЛЕННЯ СУМІШИ d-І l-ЕНАНТІОМЕРІВ 4-[1-

Country Status (29)

Country Link
US (1) US4910214A (uk)
EP (1) EP0300652B1 (uk)
JP (1) JPH0625138B2 (uk)
KR (1) KR940007311B1 (uk)
CN (1) CN1022323C (uk)
AT (1) ATE71941T1 (uk)
AU (1) AU600839B2 (uk)
BG (1) BG60473B2 (uk)
CA (1) CA1337659C (uk)
CY (2) CY1787A (uk)
DD (1) DD281807A5 (uk)
DE (2) DE3867945D1 (uk)
DK (1) DK165788C (uk)
ES (1) ES2038757T3 (uk)
FI (1) FI95375C (uk)
GB (1) GB2206880B (uk)
GR (1) GR3003878T3 (uk)
HK (1) HK56094A (uk)
HU (1) HU198693B (uk)
IE (1) IE60456B1 (uk)
IL (1) IL87076A0 (uk)
LU (1) LU91010I2 (uk)
NL (1) NL300117I2 (uk)
NO (2) NO170579C (uk)
NZ (1) NZ225362A (uk)
PT (1) PT88013B (uk)
SU (1) SU1648248A3 (uk)
UA (1) UA5560A1 (uk)
ZA (1) ZA885134B (uk)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB2281206A (en) * 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
IN187238B (uk) * 1995-06-30 2002-03-09 Astra Ab
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US5866579A (en) 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AU778522B2 (en) 1999-10-29 2004-12-09 Orion Corporation Treatment or prevention of hypotension and shock
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
JP5479086B2 (ja) 2006-03-16 2014-04-23 トリス・フアルマ・インコーポレーテツド 薬剤−イオン交換樹脂複合体を含有する放出調節製剤
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
WO2010065547A1 (en) * 2008-12-01 2010-06-10 Map Pharmaceuticals, Inc. Inhalation delivery methods and devices
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
CA2762107A1 (en) * 2009-05-15 2010-11-18 Recro Pharma, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
CN101671305A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 一种拆分美托咪定的左旋及右旋对映体的方法
CN102464619A (zh) * 2010-11-17 2012-05-23 桑迪亚医药技术（上海）有限责任公司 一种左旋4-[1-(2,3-二甲基苯基)乙基]-1r-咪唑消旋化方法
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013069025A1 (en) 2011-11-11 2013-05-16 Neon Laboratories Ltd. "process for the preparation of dexmedetomidine"
RU2692245C2 (ru) 2011-12-11 2019-06-24 Рекро Фарма, Инк. Интраназальные композиции дексмедетомидина и способы их применения
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
ITMI20120311A1 (it) * 2012-02-29 2013-08-30 Edmond Pharma Srl Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato
ES2717469T3 (es) 2012-08-15 2019-06-21 Tris Pharma Inc Comprimido masticable de metilfenidato de liberación prolongada
NZ706990A (en) * 2012-10-15 2017-12-22 Orion Corp A veterinary method of alleviating noise aversion
TWI629066B (zh) 2013-10-07 2018-07-11 帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
ES2847936T3 (es) 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
CN105175339B (zh) * 2015-10-09 2018-01-16 辰欣药业股份有限公司 一种制备盐酸右美托咪定的方法
US9717796B1 (en) 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
FR3054218B1 (fr) * 2016-07-22 2020-03-06 Universite De Rouen Procede de dedoublement de sels de baclofene
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
CN114671811A (zh) * 2022-04-14 2022-06-28 南京正科医药股份有限公司 一种右美托咪定拆分副产物的外消旋化回收方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
GB2092569B (en) * 1981-02-05 1984-09-19 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
DE3531682A1 (de) * 1985-09-05 1987-03-12 Thomae Gmbh Dr K (+)-6-chlor-5,10-dihydro-5-((1-methyl-4- piperidinyl)acetyl)-11h-dibenzo(b,e)(1,4) diazepin-11-on, seine isolierung und verwendung als arzneimittel

Also Published As

Publication number Publication date
DE10399005I2 (de) 2012-06-06
FI95375B (fi) 1995-10-13
HK56094A (en) 1994-06-03
IE882174L (en) 1989-01-16
GB2206880B (en) 1991-04-24
FI95375C (fi) 1996-01-25
SU1648248A3 (ru) 1991-05-07
KR890002030A (ko) 1989-04-07
AU600839B2 (en) 1990-08-23
FI882819A0 (fi) 1988-06-14
IL87076A0 (en) 1988-12-30
CA1337659C (en) 1995-11-28
NO2003004I2 (no) 2005-03-21
GB2206880A (en) 1989-01-18
HU198693B (en) 1989-11-28
ZA885134B (en) 1989-04-26
DK165788C (da) 1993-06-14
GR3003878T3 (uk) 1993-03-16
DD281807A5 (de) 1990-08-22
AU1894188A (en) 1989-01-19
DE3867945D1 (de) 1992-03-05
NO170579B (no) 1992-07-27
NO883155L (no) 1989-01-17
JPH0625138B2 (ja) 1994-04-06
NL300117I2 (nl) 2003-10-01
JPS6434968A (en) 1989-02-06
HUT48218A (en) 1989-05-29
DK165788B (da) 1993-01-18
ATE71941T1 (de) 1992-02-15
PT88013B (pt) 1995-03-01
ES2038757T3 (es) 1993-08-01
DE10399005I1 (de) 2003-06-05
CN1030576A (zh) 1989-01-25
EP0300652B1 (en) 1992-01-22
NO883155D0 (no) 1988-07-15
US4910214A (en) 1990-03-20
KR940007311B1 (ko) 1994-08-12
EP0300652A1 (en) 1989-01-25
CY1787A (en) 1995-10-20
CN1022323C (zh) 1993-10-06
NZ225362A (en) 1990-07-26
CY2004006I1 (el) 2009-11-04
NL300117I1 (nl) 2003-05-01
NO170579C (no) 1992-11-04
CY2004006I2 (el) 2009-11-04
DK386288A (da) 1989-01-17
BG60473B2 (bg) 1995-04-28
GB8716803D0 (en) 1987-08-19
DK386288D0 (da) 1988-07-11
PT88013A (pt) 1989-06-30
IE60456B1 (en) 1994-07-13
LU91010I2 (fr) 2003-06-19
FI882819A (fi) 1989-01-17

Similar Documents

Publication Publication Date Title
UA5560A1 (uk) СПОСІБ РОЗДІЛЕННЯ СУМІШИ d-І l-ЕНАНТІОМЕРІВ 4-[1-
DE69133406D1 (de) Herstellung von 1,3-disubstituierter imidazolsalzen
HUT62575A (en) Process for producing substituted imidazole derivatives and pharmaceutical compositions comprising same
DE3883495T2 (de) Enantiomere Derivate von Aminosäure, Verfahren zu deren Herstellung und deren therapeutische Verwendung.
AT387963B (de) Verfahren zur herstellung von neuen antidepressiven 1,2,4-triazolonverbindungen und von deren pharmazeutisch zulaessigen saeureadditionssalzen
HUP0104010A2 (hu) Eljárás 2-hidroxi-propionsavak racemát reszolválására
RU94046047A (ru) Производные аминоуксусной кислоты в виде рацемата или d- и l-энантиомеров и их фармацевтически приемлемые соли, способ получения d- и l-энантиомеров производных аминоуксусной кислоты или их фармацевтически приемлемых солей и промежуточные d- и l-энантиомеры аминоуксусной кислоты в виде цинхонидиновой соли
PH25106A (en) 1-acyl-3-(4-(2-pyrimidinyl)-1-piperazinyl) propanes, pharmaceutical composition containing said compound and method of use thereof
NO157619C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksom n,n-dim-ethylglycinester av 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazol og syreaddisjonssalter derav.
KR840006656A (ko) 1,3,4,6,7,11b-헥사하이드로-7-아릴-2H-피라지노[2,1-α]이소퀴놀린의 제조방법
DE3367099D1 (en) Sorbinal by optical resolution of precursor 6-fluro-4-ureidochroman-4-carboxylic acid
AT389511B (de) Verfahren zur herstellung der neuen (3s(z))-2-((( 1-(-2-amino-4-thiazolyl)-2-((2,2-dimethyl-4-oxo 1-(sulfooxy)-3-azetidinyl)amino)-2-oxoaethylide ) amino)oxy)essigsaeure
NZ239435A (en) Conversion of the r(-) isomer of ketoprofen to the s(+) isomer
EA200000279A1 (ru) Способ повышения оптической чистоты 2r-[1-гидрокси-1-трифторметил-3-циклопропилпропин-2-ил]-4-хлоранилина
LV5241A3 (lv) enantiomeru maisijuma sadalisanas metode 4-Ú1-(2,3-dimetilfenil)etil¾-1h-imidazola d- un l-
DK54982A (da) Fremgangsmaade til fremstilling af 4-(1-imidazolylmethyl)-kanelsyre-hydrochlorid-monohydrat
ES2003994A6 (es) Procedimiento de preparacion de nuevas 2-cloro-12-(3-dimetilamino-2-metilpropil)-12h-dibenzo(d,g) (i,3,6) dioxazocinas opticamente activas y de sus sales de adicion acidas farmaceuticamente aceptables
PT82174B (pt) Processo para a preparacao de novos derivados do imidazol e de composicoes farmaceuticas que os contem
FI96681B (fi) Menetelmä 2,2-dimetyylisyklopropaanikarboksyylihapon rasemaattipilkkomiseksi
ES2001449A6 (es) Nuevo metodo de sintesis del bifonazol
ES8301933A1 (es) "procedimiento para la preparacion de derivados de 4-(5)-alcohil-mercaptoimidazoles".
ATA200389A (de) Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
NZ240736A (en) Racemic or dextro 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole or its salts so as to reduce stress on the nervous system prior to surgical operations
HUT53854A (en) Process for the racemization of arylalkylamines